Janney Montgomery Scott LLC Has $861,000 Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Janney Montgomery Scott LLC raised its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 8.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 51,155 shares of the company’s stock after purchasing an additional 3,912 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Cellebrite DI were worth $861,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Pembroke Management LTD boosted its stake in shares of Cellebrite DI by 24.3% in the 3rd quarter. Pembroke Management LTD now owns 1,908,345 shares of the company’s stock valued at $32,137,000 after purchasing an additional 372,619 shares during the last quarter. Meitav Investment House Ltd. boosted its position in Cellebrite DI by 29.7% during the third quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company’s stock valued at $34,797,000 after acquiring an additional 473,293 shares during the last quarter. Pathway Financial Advisers LLC boosted its position in Cellebrite DI by 1,583.8% during the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after acquiring an additional 4,118 shares during the last quarter. Tower View Wealth Management LLC grew its holdings in Cellebrite DI by 1.2% during the 3rd quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company’s stock worth $2,200,000 after acquiring an additional 1,500 shares during the period. Finally, Juncture Wealth Strategies LLC raised its position in shares of Cellebrite DI by 42.2% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 59,498 shares of the company’s stock worth $1,002,000 after acquiring an additional 17,652 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CLBT shares. Bank of America raised their target price on Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Needham & Company LLC boosted their target price on shares of Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. TD Cowen raised their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Cellebrite DI from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, August 16th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $20.29.

Cellebrite DI Trading Down 1.4 %

Shares of CLBT stock opened at $17.70 on Friday. Cellebrite DI Ltd. has a 12 month low of $7.64 and a 12 month high of $21.00. The firm has a market capitalization of $3.64 billion, a PE ratio of -11.42, a price-to-earnings-growth ratio of 2.50 and a beta of 1.50. The firm has a fifty day simple moving average of $17.74 and a two-hundred day simple moving average of $14.54.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05. The company had revenue of $106.90 million during the quarter, compared to the consensus estimate of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.09 earnings per share. On average, equities analysts predict that Cellebrite DI Ltd. will post 0.31 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.